文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

血液透析患者硬化蛋白与继发性甲状旁腺功能亢进及骨代谢的关系

Interrelationships Between Sclerostin, Secondary Hyperparathyroidism, and Bone Metabolism in Patients on Hemodialysis.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究为日本10家机构654例血液透析患者的横断面与前瞻性队列研究,探讨血清硬化蛋白与骨代谢的关联。发现硬化蛋白水平较健康人高3-4倍,与较高掌骨骨密度及较低iPTH、BAP、TRACP-5b相关,但校正PTH后关联减弱,中介分析提示PTH对骨转换标志物的作用主要直接而非经硬化蛋白介导,硬化蛋白与骨折无关。

要点

  • 血透患者硬化蛋白水平较健康人高3-4倍。
  • 硬化蛋白较高与掌骨骨密度较高及骨转换标志物较低相关。
  • 校正PTH后硬化蛋白与骨转换标志物关联显著减弱。

核心结论

  • 在透析患者中,硬化蛋白对骨代谢作用有限,可能不介导PTH对骨转换的影响。

研究设计与样本

  • 横断面与前瞻性队列研究,纳入日本10家机构的654例血液透析患者。

主要发现

  • 血液透析患者硬化蛋白中位水平较健康个体高3-4倍。
  • 较高硬化蛋白水平与较高掌骨骨密度及较低iPTH、BAP、TRACP-5b水平相关。
  • 校正PTH后,硬化蛋白与骨转换标志物的关联显著减弱。
  • 中介分析提示PTH对骨转换标志物的效应主要为直接作用,而非经硬化蛋白介导。
  • 硬化蛋白水平与既往或新发骨折均无关。

临床怎么用

  • 血透患者评估骨代谢时,硬化蛋白可能不是PTH作用的主要中介,需结合PTH等指标综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure, but its role in the pathogenesis of renal bone disease remains unknown. OBJECTIVE: We aimed to explore the association of serum sclerostin with bone metabolism in patients undergoing hemodialysis, with a particular focus on parathyroid hormone (PTH)-dependent and PTH-independent pathways. METHODS: This cross-sectional and prospective cohort study included 654 patients undergoing hemodialysis at 10 facilities in Japan. We employed multivariable linear regression to explore whether sclerostin levels were associated with metacarpal bone mineral density (BMD), intact PTH, bone alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase-5b (TRACP-5b). We employed mediation analyses to explore whether and to what extent the association of PTH with bone turnover markers is mediated by sclerostin. We also compared sclerostin levels between patients with and without previous or incident fractures. RESULTS: The median sclerostin level in hemodialysis patients was 3- to 4-fold higher than that in healthy individuals. Higher sclerostin levels were associated with higher metacarpal BMD and lower levels of intact PTH, BAP, and TRACP-5b. However, the relationships of sclerostin with bone turnover markers were substantially attenuated after adjustment for PTH. Mediation analysis suggested that the effects of PTH on bone turnover markers were mainly direct rather than mediated by sclerostin. Sclerostin levels were not associated with previous or incident fractures. CONCLUSION: These findings suggest that in patients undergoing dialysis, sclerostin has only a limited role in bone metabolism and may not mediate the effect of PTH on bone turnover.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nakagawa Y, Komaba H, Hamano N, et al. Interrelationships Between Sclerostin, Secondary Hyperparathyroidism, and Bone Metabolism in Patients on Hemodialysis. J Clin Endocrinol Metab. 2022. PMID: 34423837. doi:10.1210/clinem/dgab623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。